- 全部删除
 
您的购物车当前为空
Iroxanadine (BRX-005) 是一种新型小分子MAPK p38 抑制剂,诱导p38 SAPK 的磷酸化,在用去氧肾上腺素预先收缩的豚鼠肺动脉制剂中诱导浓度依赖性松弛,可用于治疗动脉粥样硬化、糖尿病血管病,微血管心绞痛和外周动脉疾病等血管疾病。

Iroxanadine (BRX-005) 是一种新型小分子MAPK p38 抑制剂,诱导p38 SAPK 的磷酸化,在用去氧肾上腺素预先收缩的豚鼠肺动脉制剂中诱导浓度依赖性松弛,可用于治疗动脉粥样硬化、糖尿病血管病,微血管心绞痛和外周动脉疾病等血管疾病。
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 1 mg | ¥ 990  | In stock | |
| 5 mg | ¥ 2,470  | In stock | |
| 10 mg | ¥ 3,700  | In stock | |
| 25 mg | ¥ 5,970  | In stock | |
| 50 mg | ¥ 8,260  | In stock | |
| 100 mg | ¥ 10,900  | In stock | |
| 500 mg | ¥ 22,300  | In stock | 
Iroxanadine 相关产品
| 产品描述 | Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.13480-84-5  | 
| 体内活性 | Iroxanadine通过减少caspase依赖性凋亡,提高了血管内皮细胞(ECs)在缺血/再灌注应激后的存活率。将从人脐静脉培养的ECs暴露于低氧/再氧化环境中,以模拟缺血/再灌注。在再氧化的细胞中监测了Caspase激活和细胞凋亡。在低氧之前或再氧化开始时,向培养基中添加Iroxanadine(0.1-1 μM)显著减少了caspase依赖性凋亡。[1]  | 
| 别名 | BRX-235, BRX235, BRX-005, BRX005, BRX 235, BRX 005 | 
| 分子量 | 260.33 | 
| 分子式 | C14H20N4O | 
| CAS No. | 203805-20-3 | 
| Smiles | C(C1NC(=NOC1)C=2C=CC=NC2)N3CCCCC3 | 
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 45 mg/mL (172.86 mM), Sonication is recommended.   | |||||||||||||||||||||||||||||||||||
溶液配制表  | ||||||||||||||||||||||||||||||||||||
DMSO 
  | ||||||||||||||||||||||||||||||||||||
评论内容